Main Street Research LLC Purchases 8,518 Shares of Boston Scientific Corporation $BSX

Main Street Research LLC grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 2.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 381,293 shares of the medical equipment provider’s stock after buying an additional 8,518 shares during the period. Boston Scientific makes up 2.5% of Main Street Research LLC’s holdings, making the stock its 20th biggest position. Main Street Research LLC’s holdings in Boston Scientific were worth $40,955,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in BSX. Vanguard Group Inc. grew its holdings in shares of Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after purchasing an additional 1,697,945 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Boston Scientific by 5.3% during the 1st quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider’s stock worth $1,677,124,000 after purchasing an additional 834,274 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Boston Scientific by 10.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after purchasing an additional 1,383,524 shares in the last quarter. Amundi grew its holdings in shares of Boston Scientific by 2.6% during the 1st quarter. Amundi now owns 12,308,715 shares of the medical equipment provider’s stock worth $1,212,408,000 after purchasing an additional 311,034 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Boston Scientific by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 11,299,942 shares of the medical equipment provider’s stock worth $1,139,938,000 after purchasing an additional 460,580 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on BSX shares. Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Needham & Company LLC reiterated a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a research report on Friday, October 17th. Robert W. Baird raised their price objective on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $125.00 price objective on shares of Boston Scientific in a research report on Monday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific has an average rating of “Buy” and an average price target of $123.77.

Boston Scientific Trading Up 0.2%

Shares of BSX stock opened at $98.79 on Wednesday. The company has a market cap of $146.38 billion, a P/E ratio of 52.83, a PEG ratio of 2.02 and a beta of 0.61. The stock has a 50 day simple moving average of $100.48 and a two-hundred day simple moving average of $102.45. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a fifty-two week low of $84.13 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ellen M. Zane sold 2,901 shares of the business’s stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $102.24, for a total value of $296,598.24. Following the sale, the director owned 24,134 shares of the company’s stock, valued at approximately $2,467,460.16. This represents a 10.73% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 162,891 shares of company stock valued at $16,475,387. Corporate insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.